Treatment of nondysgerminomatous ovarian germ cell tumors - An analysis of69 cases

Pl. Mitchell et al., Treatment of nondysgerminomatous ovarian germ cell tumors - An analysis of69 cases, CANCER, 85(10), 1999, pp. 2232-2244
Citations number
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
ISSN journal
0008-543X → ACNP
Year of publication
2232 - 2244
SICI code
BACKGROUND. Combination chemotherapy has dramatically improved the prognosi s of patients with nondysgerminomatous ovarian germ cell tumors (NDOGCT). H owever, guidelines are needed for the identification of patients at risk of relapse. METHODS. The authors performed a retrospective analysis of women with NDOGC T managed during the period 1970-1994 at the Royal Marsden Hospital and oth er hospitals of the London Gynaecological Oncology Group. RESULTS, Sixty-nine women were included; their median follow-up was 5.7 yea rs (minimum, 12 months). The median age was 21 years (range, 4-44 years), w ith a histology of immature teratoma (IT) for 17 patients, endodermal sinus tumor (EST) for 20 patients, and mixed tumors for 32 patients. Thirty-five patients (51%) had Stage I disease. Nine patients with Stage I tumors were observed without further therapy (six with IT and three with mixed tumors) , and one relapsed. Seven patients received non-platinum-based chemotherapy , and four relapsed. A total of 52 patients were treated with platinum-base d chemotherapy, with relapse free and overall survival rates of 87% (95% co nfidence interval [CI], 73-93%) and 84% (95% CI, 70-91%), respectively. Of these patients, relapse was seen in 0 of 9 IT patients, 1 of 25 patients wi th mixed tumors, and 6 of 18 EST patients. With alpha-fetoprotein (AFP) > 1 000 kU/L, relapse was seen in 6 of 18 patients compared with 1 of 33 relaps es with lower AFP levels. In multivariate analysis, including all patients who received chemotherapy, AFP >1000kU/L (P = 0.001) and non-platinum-based chemotherapy (P = 0.005) were associated with relapse. When only patients given platinum-based treatment were considered, EST histology (P = 0.003) a nd AFP >1000 kU/L (P = 0.003) were associated with relapse in univariate an alysis; however, these factors were linked. No malignant tumor was found at second-look surgery performed on 24 patients. Of 26 women assessable for f ertility, 24 subsequently recommenced regular menstrual function, and 11 pa tients had pregnancies. CONCLUSIONS. Platinum-based chemotherapy has been confirmed to be effective in the management of patients with NDOGCT. Relapses were principally seen among patients with AFP >1000 kU/L or pure EST histology. Efforts to improv e outcome need to focus on patients with EST, whereas less intensive manage ment strategies may be appropriate for some patients with IT. Cancer 1999;8 5:2232-44. (C) 1999 American Cancer Society.